Clinical Trial Update: Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating olaparib after response to trabectedin-pegylated liposomal doxorubicin in recurrent ovarian carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Olaparib (Olaparib)
• Trabectedin-pegylated liposomal doxorubicin (trabectedin-pegylated liposomal doxorubicin)

Snippet

Sponsor: Grupo Español de Investigación en Cáncer de Ovario | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED